CDH1 and cancer: E-cad is generally considered a tumor suppressor through inhibition of β-cat nuclear translocation (Gottardi et al., 2001) and can act as oncogene through binding to EGFR/Erb receptor that triggers ERK and AKT signaling pathways providing advantage for cancer development and metastasis (Wells et al., 2008; Rodriguez et al., 2012).